Report Overview
The Global Stroke Emerging Therapies Report is projected to grow at a CAGR of 9.1% during the forecast period, increasing from USD 2.84 billion in 2026 to USD 6.23 billion by 2035.
Highlights:
- 1Expanding thrombectomy eligibility is increasing demand for adjunctive neuroprotective therapies because reperfusion alone does not fully prevent neurological damage.
- 2Adoption of tenecteplase is accelerating because single-bolus administration simplifies emergency stroke workflows.
- 3Development programs increasingly target extended treatment windows because a significant proportion of patients remain ineligible for conventional thrombolysis.
- 4Recovery-focused therapeutics are attracting investment because healthcare systems prioritize the reduction of long-term disability costs.
Stroke remains a leading cause of disability because existing therapies primarily target vessel recanalization while many patients continue experiencing irreversible neuronal injury. This limitation increases demand for therapies capable of preserving brain tissue after ischemic injury.
Healthcare systems increasingly are prioritizing functional recovery outcomes because long-term disability generates substantial economic and caregiving burdens. This pressure supports investment in regenerative therapies, neuroprotective drugs, and advanced thrombectomy technologies.
Regulatory bodies are updating treatment frameworks as evidence supporting tenecteplase and expanded thrombectomy eligibility continues to accumulate. These changes increase demand for therapies that integrate into modern stroke pathways while demonstrating measurable improvements in modified Rankin Scale (mRS) outcomes.
Stroke emerging therapies represent a strategic area where clinical need, regulatory evolution, and technological advancement converge.
Market Dynamics
Market Drivers
Expansion of Reperfusion Standards: Acute ischemic stroke treatment relies on rapid reperfusion. Treatment guidelines increasingly are endorsing tenecteplase and expanded thrombectomy use because clinical evidence continues to improve. This evolution creates pressure to optimize outcomes after recanalization. Sponsors, therefore, are developing adjunctive neuroprotective therapies. Functional recovery remains the primary outcome driver.
Unmet Need Beyond the Treatment Window: Many patients arrive outside approved thrombolytic windows. Demand is increasing for therapies that remain effective beyond early intervention periods. This limitation reduces access to current standards of care. Clinical developers, therefore are evaluating regenerative and neurorestorative mechanisms. Broader treatment eligibility becomes the expected outcome.
Rising Disability Burden: Stroke generates persistent neurological impairment. Healthcare systems increasingly are emphasizing recovery endpoints because rehabilitation costs remain substantial. Conventional interventions address vascular occlusion but not neuronal regeneration. Emerging therapies, therefore, are targeting tissue repair pathways. Long-term functional independence becomes the strategic objective.
Regulatory Support for Innovation: Regulators prioritize therapies that address substantial unmet medical needs. Clinical programs increasingly are incorporating functional outcome measures accepted by authorities. Development uncertainty, therefore, declines for differentiated assets. Sponsors continue expanding late-stage studies. Pipeline advancement becomes more predictable.
Market Restraints
Heterogeneous stroke pathology complicates patient stratification and endpoint consistency.
Narrow intervention timelines limit enrollment in acute-stage clinical trials.
High failure rates in historical neuroprotection programs increase development risk.
Market Opportunities
Neuroprotective Combination Therapy: Recanalization restores blood flow. Cellular injury nevertheless continues after reperfusion. Demand is increasing for combination regimens that address both mechanisms. Developers are evaluating adjunctive neuroprotective candidates. Improved neurological outcomes represent an opportunity.
Regenerative Medicine: Stroke causes neuronal loss. Regenerative technologies increasingly are targeting neural repair and plasticity enhancement. Recovery limitations create demand for restorative interventions. Clinical research is expanding into stem-cell and repair-focused approaches. Functional recovery potential drives investment.
Precision Stroke Care: Patient responses vary significantly. Biomarker-guided treatment selection is increasingly improving trial design. Development programs are integrating imaging and molecular profiling. More predictable efficacy outcomes create commercial opportunities.
Emerging Markets: Stroke incidence remains high across developing regions. Treatment infrastructure is increasingly improving. Demand for accessible therapies is expanding. Sponsors continue to broaden geographical clinical footprints. Commercial adoption opportunities increase.
Disease & Epidemiology Analysis
Stroke consists primarily of ischemic and hemorrhagic subtypes. Ischemic stroke represents the dominant therapeutic focus because vascular occlusion allows pharmacological intervention. Demand increasingly centers on reducing disability rather than only lowering mortality.
Aging populations are increasing stroke incidence. Cardiovascular risk factors continue driving patient volumes. This trend creates pressure on healthcare systems. Therapeutic innovation, therefore, focuses on improving recovery efficiency. Functional independence remains the principal clinical objective.
Treatment Guidelines Landscape
Area | Current Direction |
IV Thrombolysis | Tenecteplase is increasingly recognized as an alternative to alteplase. |
Mechanical Thrombectomy | Eligibility expanding to broader patient groups |
Large Vessel Occlusion | Earlier intervention remains standard. |
Post-Stroke Recovery | Greater focus on rehabilitation and functional outcomes |
Market Segmentation
By Stroke Type
Ischemic stroke dominates development activity because reperfusion and neuroprotection opportunities remain substantial. Clinical demand is increasingly shifting toward therapies capable of preserving tissue viability after vessel reopening. Treatment limitations create pressure for adjunctive interventions. Sponsors are prioritizing ischemic stroke pipelines. Development investment remains concentrated in this segment.
By Drug Type
Thrombolytics remain the therapeutic foundation because rapid reperfusion directly influences outcomes. Demand is increasingly favoring tenecteplase due to operational simplicity. Alteplase limitations create adoption pressure. Clinical guidelines support broader tenecteplase utilization. Competitive differentiation increasingly centers on administrative efficiency.
By Therapy Type
Endovascular therapy defines modern stroke intervention. Eligibility expansion is increasingly broadening patient access. Procedural success nevertheless leaves residual neurological injury. Adjunctive therapies, therefore, are entering development alongside thrombectomy pathways. Combined treatment strategies increasingly shape future demand.
Regional Analysis
North America Market Analysis
North America leads clinical innovation because advanced stroke networks support rapid diagnosis and intervention. Demand is increasingly shifting toward outcome-enhancing therapies as thrombectomy adoption matures. Recovery limitations create interest in neuroprotective agents. Sponsors, therefore, are conducting pivotal studies across the region. Regulatory engagement remains strong. Market demand focuses on functional improvement.
Europe Market Analysis
Europe maintains significant stroke research activity because coordinated stroke systems support large multicenter studies. Demand increasingly is favoring evidence-based treatment optimization. Guideline evolution creates opportunities for novel therapeutics. Sponsors, therefore, continue expanding clinical programs. Recovery-focused interventions attract growing attention.
Asia Pacific Market Analysis
Asia Pacific carries a substantial stroke burden because population size and cardiovascular risk factors remain high. Demand is increasingly focusing on therapies that improve accessibility and outcomes. Healthcare infrastructure continues expanding. Clinical research, therefore, is accelerating across major markets. Regional participation in global trials continues to increase.
Rest of the World
Healthcare modernization is increasing stroke treatment access across Latin America, the Middle East, and Africa. Treatment gaps create demand for scalable interventions. Clinical awareness continues to improve. Adoption, therefore, increasingly follows global treatment standards. Emerging therapy penetration gradually expands.
Regulatory Landscape
Regulatory authorities prioritize therapies that demonstrate meaningful functional benefit. Clinical programs increasingly are using mRS-based endpoints because they reflect real-world disability outcomes. This approach improves consistency between sponsors and regulators.
Guideline updates increasingly are incorporating evidence supporting tenecteplase and broader thrombectomy eligibility. These changes reduce uncertainty for developers. Clinical development, therefore, is aligning with evolving standards of care. Regulatory pathways increasingly support differentiated stroke innovations.
Pipeline Analysis
The pipeline is increasingly diversifying beyond thrombolysis because unmet recovery needs remain substantial. Neuroprotective agents, regenerative therapies, and adjunctive reperfusion approaches dominate development activity. Sovateltide continues advancing through global Phase III evaluation while demonstrating recovery-focused potential.
Intra-arterial tenecteplase development continues to expand because investigators are exploring improved reperfusion in medium vessel occlusions. Phase III recruitment remains active.
Reimbursement Landscape
Reimbursement decisions primarily depend on disability reduction. Healthcare systems increasingly evaluate long-term economic benefits because stroke-related care costs remain substantial. Therapies demonstrating improved functional independence possess stronger reimbursement potential.
Outcome-based evidence increasingly influences payer decisions. Clinical developers, therefore, are emphasizing recovery endpoints alongside mortality and safety measures. Reimbursement attractiveness depends on measurable reductions in long-term disability burden.
Competitive Landscape
Genentech
Genentech remains strategically distinct because it commercialized both alteplase and tenecteplase for acute ischemic stroke. Demand increasingly favors streamlined thrombolysis. This shift strengthens tenecteplase adoption. The company benefits from guideline support and established physician familiarity. Its position remains anchored in acute reperfusion leadership.
Boehringer Ingelheim
Boehringer Ingelheim maintains relevance through cardiovascular and anticoagulation expertise. Stroke management increasingly emphasizes prevention and secondary risk reduction. Demand therefore supports continued involvement in cerebrovascular care. Strategic opportunities remain linked to integrated cardiovascular portfolios.
F. Hoffmann-La Roche Ltd
Roche benefits from diagnostics capabilities that support precision stroke management. Biomarker utilization increasingly influences treatment selection. This trend creates synergy between diagnostics and therapeutics. The company, therefore, maintains strategic positioning within evolving stroke pathways.
Bayer AG
Bayer leverages anticoagulation and cardiovascular experience. Stroke prevention demand continues to increase because aging populations elevate risk exposure. This dynamic supports long-term relevance. Portfolio integration remains a strategic advantage.
Johnson & Johnson
Johnson & Johnson maintains strengths in medical technology and intervention-focused healthcare. Endovascular adoption increasingly expands procedural opportunities. This trend supports strategic participation in stroke management ecosystems. Technology integration remains central to differentiation.
Daiichi Sankyo
Daiichi Sankyo benefits from cardiovascular expertise and global development capabilities. Stroke management increasingly intersects with antithrombotic innovation. Clinical demand supports ongoing strategic relevance. Global market access remains a competitive strength.
Key Developments
April 2026: The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine. The study investigated the safety and efficacy of administering the oral factor XIa inhibitor asundexian at a daily dose of 50 mg in addition to antiplatelet therapy to reduce the risk of recurrent ischemic stroke. Treatment with asundexian resulted in lower risks of ischemic stroke and major cardiovascular events than placebo, without a higher risk of major bleeding.
December 2025: NuvOx Therapeutics announced the first patient enrolled in their Phase IIb stroke trial. NuvOx is conducting a Phase IIb clinical trial as a radiosensitizer in the treatment of glioblastoma, and has started a Phase IIb clinical trial for stroke treatment. This represents the company's expansion into stroke therapeutics alongside their cancer treatment programs.
November 2025: UCLA discovered the first stroke rehabilitation drug to repair the brain and reestablish brain connections in mice. The drug, called CSLH-001, was able to replicate the movement recovered in physical rehabilitation, the traditional treatment for stroke recovery. This groundbreaking finding represents a potential breakthrough in stroke rehabilitation by offering a pharmacological approach to help the brain repair damaged connections and restore function.
Strategic Insights and Future Market Outlook
The stroke emerging therapies landscape is moving beyond reperfusion because functional recovery increasingly determines treatment value. This transition creates demand for therapies capable of preserving neural tissue, enhancing repair mechanisms, and extending intervention opportunities.
Clinical development increasingly is focusing on combination approaches because no single mechanism fully addresses stroke pathology. Neuroprotection, regeneration, and optimized reperfusion are converging within next-generation treatment strategies. Sponsors continue expanding late-stage studies to capture this opportunity.
Regulatory support, evolving guidelines, and growing disability-related healthcare costs create favorable conditions for innovation. The market increasingly rewards therapies demonstrating measurable recovery benefits rather than procedural success alone.
Stroke treatment enters a phase where restoring blood flow no longer defines a competitive advantage by itself. Therapies that improve long-term neurological independence are shaping future demand, directing sponsor investment, and determining the next wave of clinical and commercial success.
Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 2.84 billion |
| Total Market Size in 2035 | USD 6.23 billion |
| Forecast Unit | USD Billion |
| Growth Rate | 9.1% |
| Study Period | 2021 to 2035 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2035 |
| Segmentation | Stroke Type, Drug Type, Therapy Type, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
By Geography
Key Countries Analysis
Regulatory & Policy Landscape
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Report Scope and Objectives
1.2 Stroke Market Overview
1.3 Key Findings
1.3.1 Epidemiology Highlights
1.3.2 Current Treatment Landscape
1.3.3 Emerging Therapy Trends
1.3.4 Market Growth Opportunities
1.4 Analyst Perspective
1.5 Strategic Recommendations
2. DISEASE & EPIDEMIOLOGY ANALYSIS
2.1 Introduction to Stroke
2.1.1 Definition and Clinical Background
2.1.2 Disease Burden
2.1.3 Pathophysiology
2.2 Stroke Classification
2.2.1 Ischemic Stroke
2.2.2 Hemorrhagic Stroke
2.2.2.1 Intracerebral Hemorrhage
2.2.2.2 Subarachnoid Hemorrhage
2.2.3 Transient Ischemic Attack (TIA)
2.3 Risk Factors and Comorbidities
2.3.1 Hypertension
2.3.2 Atrial Fibrillation
2.3.3 Diabetes Mellitus
2.3.4 Dyslipidemia
2.3.5 Obesity
2.3.6 Smoking and Alcohol Use
2.4 Epidemiology Analysis
2.4.1 Global Prevalence
2.4.2 Global Incidence
2.4.3 Mortality Analysis
2.4.4 Disability-Adjusted Life Years (DALYs)
2.4.5 Recurrence Rates
2.5 Epidemiology by Stroke Type
2.5.1 Ischemic Stroke Epidemiology
2.5.2 Hemorrhagic Stroke Epidemiology
2.5.3 TIA Epidemiology
2.6 Epidemiology by Age Group
2.7 Epidemiology by Gender
2.8 Diagnosed and Treated Patient Pool Analysis
2.9 Epidemiology Forecast
3. MARKET DYNAMICS
3.1 Market Overview
3.2 Market Drivers
3.2.1 Rising Global Stroke Burden
3.2.2 Aging Population
3.2.3 Increasing Awareness and Early Diagnosis
3.2.4 Expansion of Stroke Centers
3.2.5 Advancements in Reperfusion Therapies
3.3 Market Restraints
3.3.1 Limited Therapeutic Window
3.3.2 High Treatment Costs
3.3.3 Access Disparities
3.3.4 Clinical Trial Challenges
3.4 Market Opportunities
3.4.1 Neuroprotection Therapies
3.4.2 Regenerative Medicine Approaches
3.4.3 AI-Enabled Stroke Management
3.4.4 Precision Medicine
3.5 Market Challenges
3.6 Porter’s Five Forces Analysis
3.7 PESTLE Analysis
3.8 Value Chain Analysis
3.9 Unmet Needs Assessment
4. COMMERCIAL & MARKET ACCESS
4.1 Market Access Overview
4.2 Reimbursement Landscape
4.3 Pricing Analysis
4.4 Health Technology Assessment Trends
4.5 Stakeholder Analysis
4.5.1 Physicians
4.5.2 Hospitals
4.5.3 Payers
4.5.4 Patients
4.6 Patient Journey Analysis
4.7 Treatment Adoption Trends
5. INNOVATION & PIPELINE LANDSCAPE
5.1 Innovation Overview
5.2 Emerging Therapeutic Modalities
5.2.1 Small Molecules
5.2.2 Monoclonal Antibodies
5.2.3 Cell Therapies
5.2.4 Gene-Based Therapies
5.2.5 Neuroprotective Agents
5.3 Pipeline Analysis by Development Stage
5.3.1 Discovery and Preclinical
5.3.2 Phase I
5.3.3 Phase II
5.3.4 Phase III
5.4 Pipeline Analysis by Mechanism of Action
5.4.1 Thrombolytic Enhancement
5.4.2 Neuroprotection
5.4.3 Anti-Inflammatory Approaches
5.4.4 Stem Cell-Based Regeneration
5.4.5 Vascular Repair and Remodeling
5.5 Pipeline Analysis by Modality
5.6 Clinical Trial Landscape
5.6.1 Active Clinical Trials
5.6.2 Completed Clinical Trials
5.6.3 Upcoming Milestones
5.7 Licensing, Partnerships, and Collaborations
5.8 Funding and Investment Trends
5.9 Future Innovation Outlook
6. TREATMENT LANDSCAPE
6.1 Current Standard of Care
6.2 Treatment Algorithm
6.3 Acute Stroke Management
6.3.1 Intravenous Thrombolysis
6.3.2 Mechanical Thrombectomy
6.3.3 Antiplatelet Therapy
6.3.4 Anticoagulation Therapy
6.4 Secondary Prevention Strategies
6.5 Rehabilitation and Recovery Approaches
6.6 Approved Drug Landscape
6.6.1 Alteplase
6.6.2 Tenecteplase
6.6.3 Aspirin
6.6.4 Clopidogrel
6.6.5 Ticagrelor
6.6.6 Rivaroxaban
6.6.7 Apixaban
6.6.8 Dabigatran
6.6.9 Edoxaban
6.7 Emerging Therapies Assessment
6.8 Comparative Clinical Assessment
7. GLOBAL STROKE EMERGING THERAPIES REPORT SIZE & FORECAST
7.1 Market Size Analysis (Historical)
7.2 Market Forecast Methodology
7.3 Market Revenue Forecast
7.3.1 By Therapy Type
7.3.2 By Stroke Type
7.3.3 By Route of Administration
7.3.4 By End User
7.4 Market Attractiveness Analysis
7.5 Scenario Analysis
8. GLOBAL STROKE EMERGING THERAPIES REPORT SEGMENTATION
8.1 By Stroke Type
8.1.1 Ischemic Stroke
8.1.1.1. Thrombotic
8.1.1.2. Embolic
8.1.2 Hemorrhagic Stroke
8.1.3 Transient Ischemic Attack
8.1.4 Others
8.2 By Drug Type
8.2.1 Thrombolytics
8.2.2 Antiplatelets
8.2.3 Anticoagulants
8.2.4 Antihypertensives
8.2.5 Others
8.3 By Therapy Type
8.3.1 IV Medication
8.3.2 Endovascular Therapy
8.3.3 Surgical Procedures
8.3.3.1 Mechanical Thrombectomy
8.3.3.2 Carotid Endarterectomy (CEA)
8.3.3.3 Other Emerging Therapies
8.4 By Severity Type
8.4.1 Mild
8.4.2 Moderate
8.4.3 Severe
8.5 By End User
8.5.1 Hospitals
8.5.2 Specialty Clinics
8.5.3 Rehabilitation Centers
8.5.4 Others
9. GEOGRAPHICAL ANALYSIS (REGIONAL LEVEL)
9.1 North America
9.1.1 Market Size and Forecast
9.1.2 Demand Drivers
9.1.3 Regional Regulatory Overview
9.1.4 Competitive Intensity
9.2 Europe
9.2.1 Market Size and Forecast
9.2.2 Demand Drivers
9.2.3 Regional Regulatory Overview
9.2.4 Competitive Intensity
9.3 Asia-Pacific
9.3.1 Market Size and Forecast
9.3.2 Demand Drivers
9.3.3 Regional Regulatory Overview
9.3.4 Competitive Intensity
9.4 Latin America
9.4.1 Market Size and Forecast
9.4.2 Demand Drivers
9.4.3 Regional Regulatory Overview
9.4.4 Competitive Intensity
9.5 Middle East & Africa
9.5.1 Market Size and Forecast
9.5.2 Demand Drivers
9.5.3 Regional Regulatory Overview
9.5.4 Competitive Intensity
10. KEY COUNTRIES ANALYSIS
10.1 United States
10.1.1 Market Size
10.1.2 Epidemiology
10.1.3 Regulatory Framework
10.1.4 Reimbursement Landscape
10.1.5 Key Companies and Products Presence
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa
10.16.1 Market Size
10.16.2 Epidemiology
10.16.3 Regulatory Framework
10.16.4 Reimbursement Landscape
10.16.5 Key Companies and Products Presence
11. REGULATORY & POLICY LANDSCAPE
11.1 Regulatory Overview
11.2 United States (FDA)
11.2.1 Drug Approval Pathways
11.2.2 Expedited Programs
11.3 Europe (EMA)
11.3.1 Centralized Approval Process
11.3.2 Market Authorization Framework
11.4 Japan (PMDA)
11.5 India (CDSCO)
11.6 China (NMPA)
11.7 Orphan and Special Designations
11.8 Clinical Trial Regulations
11.9 Pharmacovigilance Requirements
11.10 Future Regulatory Trends
12. COMPETITIVE LANDSCAPE
12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Positioning Analysis
12.4 Pipeline Competitiveness Assessment
12.5 Strategic Initiatives
12.5.1 Mergers and Acquisitions
12.5.2 Collaborations and Partnerships
12.5.3 Licensing Agreements
12.5.4 R&D Investments
12.6 SWOT Analysis
12.7 Key Success Factors
13. COMPANY PROFILES
13.1 Genentech
13.1.1 Company Overview
13.1.2 Approved Products: Activase (alteplase), TNKase (tenecteplase)
13.1.3 Key Indications
13.1.4 Stroke-Related Development Activities
13.1.5 Strategic Outlook
13.2 Boehringer Ingelheim
13.2.1 Company Overview
13.2.2 Approved Products: Actilyse (alteplase), Pradaxa (dabigatran)
13.2.3 Key Indications
13.2.4 Relevant Pipeline Programs
13.2.5 Strategic Outlook
13.3 F. Hoffmann-La Roche Ltd
13.3.1 Company Overview
13.3.2 Approved Products and Neurology Portfolio Overview
13.3.3 Key Indications
13.3.4 Relevant Pipeline Programs
13.3.5 Strategic Outlook
13.4 Novartis AG
13.4.1 Company Overview
13.4.2 Approved Products: Entresto (sacubitril/valsartan)
13.4.3 Key Indications
13.4.4 Relevant Pipeline Programs
13.4.5 Strategic Outlook
13.5 Bayer AG
13.5.1 Company Overview
13.5.2 Approved Products: Xarelto (rivaroxaban)
13.5.3 Key Indications
13.5.4 Relevant Pipeline Programs
13.5.5 Strategic Outlook
13.6 Johnson & Johnson
13.6.1 Company Overview
13.6.2 Approved Products: Xarelto (rivaroxaban alliance markets)
13.6.3 Key Indications
13.6.4 Relevant Pipeline Programs
13.6.5 Strategic Outlook
13.7 Daiichi Sankyo
13.7.1 Company Overview
13.7.2 Approved Products: Lixiana/Savaysa (edoxaban)
13.7.3 Key Indications
13.7.4 Relevant Pipeline Programs
13.7.5 Strategic Outlook
13.8 Sanofi
13.8.1 Company Overview
13.8.2 Approved Products Relevant to Cardiovascular and Neurological Care
13.8.3 Key Indications
13.8.4 Relevant Pipeline Programs
13.8.5 Strategic Outlook
13.9 Novo Nordisk
13.9.1 Company Overview
13.9.2 Approved Products: Ozempic (semaglutide), Rybelsus (semaglutide)
13.9.3 Key Indications
13.9.4 Cardiovascular Risk Reduction Programs
13.9.5 Strategic Outlook
13.10 AstraZeneca PLC
13.10.1 Company Overview
13.10.2 Approved Products: Brilinta/Brilique (ticagrelor)
13.10.3 Key Indications
13.10.4 Relevant Pipeline Programs
13.10.5 Strategic Outlook
13.11 Merck & Co., Inc.
13.11.1 Company Overview
13.11.2 Approved Products Relevant to Stroke Risk Management
13.11.3 Key Indications
13.11.4 Relevant Pipeline Programs
13.11.5 Strategic Outlook
13.12 GlaxoSmithKline plc
13.12.1 Company Overview
13.12.2 Approved Products Relevant to Stroke Prevention and Comorbidities
13.12.3 Key Indications
13.12.4 Relevant Pipeline Programs
13.12.5 Strategic Outlook
13.13 Eli Lilly and Company
13.13.1 Company Overview
13.13.2 Approved Products: Mounjaro (tirzepatide), Trulicity (dulaglutide)
13.13.3 Key Indications
13.13.4 Cardiometabolic Risk Reduction Programs
13.13.5 Strategic Outlook
13.14 AbbVie Inc.
13.14.1 Company Overview
13.14.2 Approved Products Relevant to Neurology Portfolio
13.14.3 Key Indications
13.14.4 Relevant Pipeline Programs
13.14.5 Strategic Outlook
14. FUTURE OUTLOOK
14.1 Market Forecast Summary
14.2 Future Treatment Paradigm Evolution
14.3 Emerging Technologies Impact
14.4 Pipeline Commercialization Outlook
14.5 Investment Opportunities
14.6 Strategic Recommendations
14.7 Long-Term Market Outlook
15. METHODOLOGY
15.1 Research Objectives
15.2 Research Design
15.3 Secondary Research Methodology
15.4 Primary Research Methodology
15.5 Data Validation and Triangulation
15.6 Forecasting Methodology
15.7 Assumptions and Limitations
15.8 Abbreviations
15.9 References and Data Sources
Navigate
Trusted by the world's leading organizations
